Related Experiment Video
Updated: May 6, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.3K
Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
Hojabr Kakavand1, Richard A Scolyer, John F Thompson
1Melanoma Institute Australia; North Sydney, NSW Australia ; The University of Sydney; Sydney, NSW Australia.
Oncoimmunology
|November 15, 2013
Abstract:
Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.
